Lugano, Switzerland, 7 May 2025 – ESMO Breast Cancer 2025 will take place between 14-17 May in Munich, Germany, bringing together international experts to present and discuss the latest advances in breast cancer research and care. The congress will cover a broad spectrum of topics, from translational research and developments in molecular and functional diagnostics to emerging therapies. Among the key themes are the clinical application of circulating tumour DNA (ctDNA), the evolving role of immunotherapies and antibody-drug conjugates (ADCs), new approaches for managing breast cancer in younger patients.
The event will be accessible both in person and online, with sessions available via live stream on the Virtual Congress Platform.
Programme picks
-
Long-term data on survival benefits and safety in patients with early HER2-positive operable breast cancer at high risk of relapse, 11.3 years after receiving standard-of-care combination therapy.
-
Related content: LBA 1
-
-
Novel findings from large trials on predictive biomarkers for foregoing chemotherapy in early breast cancer treated with endocrine-based therapy.
-
Related content: 189O, 190O
-
-
Novel data on the value of ctDNA as a prognostic and dynamic biomarker in various breast cancer settings and its utility in practice to guide decision-making on therapies.
-
New evidence on the role of tumour-infiltrating lymphocytes (TILs) in the prognostication of early-stage triple negative breast cancer, within a broader effort to ‘right-size’ adjuvant therapy based on patients’ individual risk profiles.
-
Related content: 2O; Educational session
-
-
Promising emerging targets for antibody-drug conjugates (ADCs) across different breast cancer settings, along with insights into resistance mechanisms and future directions in the field.
-
New data on disease outcome, pregnancy and fetal outcomes after breast cancer.
-
“Development of targeted therapies for HR+ breast cancer”, Award Lecture by Gabriel N. Hortobagyi, recipient of the 2025 ESMO Breast Cancer Award, 14 May, 13:00-13:40 CEST.
-
“Who benefits from immunotherapy for breast cancer?”, Keynote lecture by Sherene Loi, 14 May, 15:35-16:00 CEST.
- “A decade of Breast Cancer in Young Women: What we have done and where we are going” Keynote Lecture by Ann H. Partridge, 16 May,16:45- 17:15 CEST.
The abstracts will be published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for ESMO Breast Cancer 2025. To apply for press accreditation, please fill out the form available here. Please be kindly informed that onsite press accreditation will not be available.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Breast Cancer 2025 and the official congress hashtag #ESMOBreast25. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, Bluesky
About the European Society for Medical Oncology (ESMO)
Representing more than 40,000 oncology professionals from 179 countries and territories, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
Media Contact
Vanessa Pavinato
European Society for Medical Oncology
media@esmo.org
Office: +41 91 973 55 71
Keywords
bu içeriği en az 2000 kelime olacak şekilde ve alt başlıklar ve madde içermiyecek şekilde ünlü bir science magazine için İngilizce olarak yeniden yaz. Teknik açıklamalar içersin ve viral olacak şekilde İngilizce yaz. Haber dışında başka bir şey içermesin. Haber içerisinde en az 12 paragraf ve her bir paragrafta da en az 50 kelime olsun. Cevapta sadece haber olsun. Ayrıca haberi yazdıktan sonra içerikten yararlanarak aşağıdaki başlıkların bilgisi var ise haberin altında doldur. Eğer yoksa bilgisi ilgili kısmı yazma.:
Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits:
Keywords
